Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Trans R Soc Trop Med Hyg ; 85(2): 214-6, 1991.
Article in English | MEDLINE | ID: mdl-1909469

ABSTRACT

In a randomized prospective trial N-methyl-glucamine antimoniate (Glucantime) and human recombinant interferon-gamma were infiltrated around lesions of cutaneous leishmaniasis caused by Leishmania tropica in Syria. A previous trial had shown that intradermal application of interferon-gamma promoted the healing of similar lesions in the study area. Twenty patients with 38 lesions received 1-3 ml Glucantime and 20 patients with 37 lesions received 25 micrograms of interferon-gamma intradermally once weekly for 5 consecutive weeks. While all lesions treated with Glucantime were free of parasites after the third injection, only 69% of those treated with interferon-gamma were parasitologically cured by week 10. Within 10 weeks, lesions treated with Glucantime healed completely in 29/38, and partially in 9/38, cases, whereas 1/37 and 13/37 lesions treated with interferon-gamma healed completely and partially, respectively. Perilesional application of Glucantime was highly effective and superior to interferon-gamma for treatment of cutaneous leishmaniasis caused by L. tropica.


Subject(s)
Antiprotozoal Agents/administration & dosage , Interferon-gamma/administration & dosage , Leishmaniasis/drug therapy , Meglumine/administration & dosage , Organometallic Compounds/administration & dosage , Administration, Cutaneous , Adolescent , Adult , Female , Humans , Immunoglobulins/analysis , Injections/adverse effects , Leishmaniasis/immunology , Male , Meglumine Antimoniate , Pain/etiology , Recombinant Proteins
2.
Lancet ; 1(8650): 1287-92, 1989 Jun 10.
Article in English | MEDLINE | ID: mdl-2566825

ABSTRACT

The clinical and immunological evolution of lesions in cutaneous leishmaniasis was assessed after treatment with human recombinant gamma interferon (rIFN-gamma). 3 weeks after rIFN-gamma treatment of lesions due to Leishmania braziliensis guyanensis, 12/13 had become smaller compared with 6/13 control lesions; only 4 treated lesions were free of parasites. 9 of 13 L tropica lesions treated with rIFN-gamma resolved completely within 4-8 weeks of treatment. An acute inflammatory reaction around treated lesions was more common in lesions due to L tropica. There were no other local or systemic adverse reactions. Histological and immunohistochemical studies indicate that local application of rIFN-gamma enhances cell-mediated immune responses and thus promotes healing of cutaneous leishmaniasis.


Subject(s)
Interferon-gamma/administration & dosage , Leishmaniasis/therapy , Acute Disease , Administration, Topical , Adolescent , Adult , Animals , Antibodies, Protozoan/analysis , Biopsy , Brazil , Clinical Trials as Topic , Female , HLA-DR Antigens/analysis , Humans , Immunity, Cellular , Immunoglobulin E/analysis , Injections, Subcutaneous , Interferon-gamma/adverse effects , Interferon-gamma/therapeutic use , Leishmania braziliensis/immunology , Leishmaniasis/immunology , Leishmaniasis/pathology , Leukocyte Count , Male , Middle Aged , Receptors, Interleukin-2/analysis , Recombinant Proteins , Skin/pathology , Syria , T-Lymphocytes/immunology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...